<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03544996</url>
  </required_header>
  <id_info>
    <org_study_id>TDS INS-001</org_study_id>
    <nct_id>NCT03544996</nct_id>
  </id_info>
  <brief_title>Transdermally Delivered Human Insulin Product</brief_title>
  <official_title>A Comparison of Injected Insulin Replacement Therapy With A Novel Transdermally Delivered Human Insulin Product</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Transdermal Delivery Solutions Corp</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Transdermal Delivery Solutions Corp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Early Feasibility Study of a device formulation to deliver human insulin across intact
      skin
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An attempt was made to formulate an insulin product that would complex human insulin in a
      stable anhydrous solution and when applied to the skin enable the uptake and release of
      insulin in a brittle T1D patient.

      A series of formulations were produced at varing dose strengths and in conjunction with
      injected insulin products, applied and serum glucose measured to ascertain response and
      optimize a fomrula to be submitted for IND approval.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 9, 2017</start_date>
  <completion_date type="Actual">February 4, 2018</completion_date>
  <primary_completion_date type="Actual">February 4, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin response</measure>
    <time_frame>8-24 hours</time_frame>
    <description>Measurement of down modulation of serum glucose as measured by a standard blood glucose meter not otherwise attributable to injected insulin</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1</enrollment>
  <condition>Hypoinsulinemia</condition>
  <arm_group>
    <arm_group_label>TD Insulin Pilot</arm_group_label>
    <description>Test of novel transdermal insulin (TD Insulin) formulations</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>TD Insulin</intervention_name>
    <description>Human Insulin USP formulated in a solution capable of transdermal delivery.</description>
    <arm_group_label>TD Insulin Pilot</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Single patient, brittle T1D patient
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Brittle T1D patient with poor insulin sensitivity requiring more than 3,000 IUs on
             insulin a day

        Exclusion Criteria:

          -  High insulin sensitivity

          -  well managed serum glucose
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>61 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William D Kirsh, D.O.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sentry Data Systems</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Langford Research Institute</name>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <zip>33410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 22, 2018</study_first_submitted>
  <study_first_submitted_qc>May 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2018</study_first_posted>
  <last_update_submitted>June 2, 2018</last_update_submitted>
  <last_update_submitted_qc>June 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insulin, needle-less, transdermal</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

